Data from the Phase III SATURN Study Show Tarceva Improved Progression-Free Survival When Used as a First-Line Maintenance Th...
May 14 2009 - 5:01PM
Business Wire
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced detailed
results from the Phase III SATURN study of Tarceva� (erlotinib) as
a single agent, first-line maintenance therapy for patients with
advanced non-small cell lung cancer (NSCLC) who did not progress
following first-line treatment with platinum-based chemotherapy.
The study met both of its co-primary endpoints by demonstrating a
statistically significant 41% improvement in the time patients live
without their disease worsening (as measured by progression free
survival, or PFS) compared with placebo (Hazard Ratio = 0.71,
p-value
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Osi Pharmaceuticals Inc. (MM) (NASDAQ): 0 recent articles
More OSI Pharmaceuticals, Inc. News Articles